Astellas Pharma Inc., a leading biotechnology company, has announced a variety of initiatives and developments that reflects its active involvement in diverse areas like research, drug discovery and therapy. They are driving
sustainability through collaboration and are currently involved in numerous projects. Among these is a
$2.2bn gene therapy deal with AviadoBio Ltd and an agreement with YASKAWA to establish a
joint venture focused on cell therapy manufacturing. Providing innovative solutions, Astellas recently unveiled their new
Life Sciences Center in Cambridge, Massachusetts and also made advancements with IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy getting U.S. FDA approval. Besides, Astellas demonstrated involvement in breakthrough research such as the preferred use of their drug VYLOY™ (zolbetuximab-clzb) for the treatment of advanced Gastric and GEJ Cancer, and longer-term use of IZERVAY in treating vision loss. There's also a turbulent episode with the detention of an employee in China. Despite some missed earnings, Astellas Pharma Inc. continued focusing on R&D investments, recently revealing a diversified approach to
innovation partnerships in DEGITIVA™ for management of heart failure and unveiling new, state-of-the-art West Coast innovation center.
Astellas Pharma Inc. News Analytics from Wed, 19 Jul 2023 07:00:00 GMT to Thu, 20 Mar 2025 21:00:00 GMT -
Rating 3
- Innovation 4
- Information 6
- Rumor -7
